Bio-Thera Solutions

Executive Summary

Bio-Thera Solutions is a commercial-stage Chinese biopharmaceutical company specializing in innovative biologics and biosimilars for oncology and immunology. The company has built a robust pipeline of monoclonal antibodies and antibody-drug conjugates, leveraging its proprietary cell line development and manufacturing platform. Key marketed products include Batoclimab and biosimilars of bevacizumab and trastuzumab, with several late-stage candidates approaching regulatory decisions. In 2025, the FDA accepted its BLAs for BAT2206 (ustekinumab biosimilar) and BAT1806 (tocilizumab biosimilar), with PDUFA dates in 2026. Additionally, the company is advancing novel programs such as BAT1006 (anti-PD-1) and BAT8001 (ADC). With a growing portfolio and expanding global footprint, Bio-Thera is well-positioned to capture market share in the biosimilar space while advancing innovative therapies. However, regulatory risks and competition from established players remain key challenges.

Upcoming Catalysts (preview)

• Q2 2026FDA Approval Decision for BAT2206 (Ustekinumab Biosimilar)75% success
• Q3 2026FDA Approval Decision for BAT1806 (Tocilizumab Biosimilar)70% success
• Q4 2026NMPA Filing or Update for BAT4306F (Abatacept Biosimilar)60% success